vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and OFG BANCORP (OFG). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $184.3M, roughly 1.5× OFG BANCORP). OFG BANCORP runs the higher net margin — 30.3% vs -45.7%, a 76.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 0.9%). OFG BANCORP produced more free cash flow last quarter ($199.3M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.8%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
GH vs OFG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $184.3M |
| Net Profit | $-128.5M | $55.9M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 25.7% |
| Net Margin | -45.7% | 30.3% |
| Revenue YoY | 39.4% | 0.9% |
| Net Profit YoY | -15.8% | 11.0% |
| EPS (diluted) | $-1.01 | $1.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $184.3M | ||
| Q3 25 | $265.2M | $186.2M | ||
| Q2 25 | $232.1M | $182.4M | ||
| Q1 25 | $203.5M | $178.6M | ||
| Q4 24 | $201.8M | $182.7M | ||
| Q3 24 | $191.5M | $174.7M | ||
| Q2 24 | $177.2M | $179.8M | ||
| Q1 24 | $168.5M | $174.4M |
| Q4 25 | $-128.5M | $55.9M | ||
| Q3 25 | $-92.7M | $51.8M | ||
| Q2 25 | $-99.9M | $51.8M | ||
| Q1 25 | $-95.2M | $45.6M | ||
| Q4 24 | $-111.0M | $50.3M | ||
| Q3 24 | $-107.8M | $47.0M | ||
| Q2 24 | $-102.6M | $51.1M | ||
| Q1 24 | $-115.0M | $49.7M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 25.7% | ||
| Q3 25 | -37.3% | 33.0% | ||
| Q2 25 | -45.9% | 36.1% | ||
| Q1 25 | -54.6% | 33.3% | ||
| Q4 24 | -62.4% | 28.9% | ||
| Q3 24 | -61.3% | 35.4% | ||
| Q2 24 | -56.8% | 39.6% | ||
| Q1 24 | -59.2% | 38.9% |
| Q4 25 | -45.7% | 30.3% | ||
| Q3 25 | -35.0% | 27.8% | ||
| Q2 25 | -43.0% | 28.4% | ||
| Q1 25 | -46.8% | 25.5% | ||
| Q4 24 | -55.0% | 27.6% | ||
| Q3 24 | -56.3% | 26.9% | ||
| Q2 24 | -57.9% | 28.4% | ||
| Q1 24 | -68.2% | 28.5% |
| Q4 25 | $-1.01 | $1.27 | ||
| Q3 25 | $-0.74 | $1.16 | ||
| Q2 25 | $-0.80 | $1.15 | ||
| Q1 25 | $-0.77 | $1.00 | ||
| Q4 24 | $-0.90 | $1.10 | ||
| Q3 24 | $-0.88 | $1.00 | ||
| Q2 24 | $-0.84 | $1.08 | ||
| Q1 24 | $-0.94 | $1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $1.0B |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.4B |
| Total Assets | $2.0B | $12.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $1.0B | ||
| Q3 25 | $580.0M | $740.3M | ||
| Q2 25 | $629.1M | $851.8M | ||
| Q1 25 | $698.6M | $710.6M | ||
| Q4 24 | $525.5M | $591.1M | ||
| Q3 24 | $585.0M | $680.6M | ||
| Q2 24 | $933.7M | $740.4M | ||
| Q1 24 | $1.0B | $754.4M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $1.4B | ||
| Q3 25 | $-354.5M | $1.4B | ||
| Q2 25 | $-305.5M | $1.3B | ||
| Q1 25 | $-250.8M | $1.3B | ||
| Q4 24 | $-139.6M | $1.3B | ||
| Q3 24 | $-60.1M | $1.3B | ||
| Q2 24 | $-1.6M | $1.2B | ||
| Q1 24 | $68.3M | $1.2B |
| Q4 25 | $2.0B | $12.5B | ||
| Q3 25 | $1.3B | $12.2B | ||
| Q2 25 | $1.3B | $12.2B | ||
| Q1 25 | $1.3B | $11.7B | ||
| Q4 24 | $1.5B | $11.5B | ||
| Q3 24 | $1.5B | $11.5B | ||
| Q2 24 | $1.6B | $11.3B | ||
| Q1 24 | $1.7B | $11.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $217.7M |
| Free Cash FlowOCF − Capex | $-54.2M | $199.3M |
| FCF MarginFCF / Revenue | -19.3% | 108.1% |
| Capex IntensityCapex / Revenue | 9.9% | 10.0% |
| Cash ConversionOCF / Net Profit | — | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $345.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $217.7M | ||
| Q3 25 | $-35.4M | $39.5M | ||
| Q2 25 | $-60.3M | $35.9M | ||
| Q1 25 | $-62.7M | $83.1M | ||
| Q4 24 | $-64.5M | $252.5M | ||
| Q3 24 | $-51.1M | $58.1M | ||
| Q2 24 | $-94.0M | $95.1M | ||
| Q1 24 | $-30.3M | $61.0M |
| Q4 25 | $-54.2M | $199.3M | ||
| Q3 25 | $-45.8M | $35.5M | ||
| Q2 25 | $-65.9M | $31.8M | ||
| Q1 25 | $-67.1M | $78.7M | ||
| Q4 24 | $-83.4M | $231.2M | ||
| Q3 24 | $-55.3M | $51.8M | ||
| Q2 24 | $-99.1M | $90.4M | ||
| Q1 24 | $-37.2M | $54.8M |
| Q4 25 | -19.3% | 108.1% | ||
| Q3 25 | -17.3% | 19.1% | ||
| Q2 25 | -28.4% | 17.4% | ||
| Q1 25 | -33.0% | 44.1% | ||
| Q4 24 | -41.3% | 126.5% | ||
| Q3 24 | -28.9% | 29.6% | ||
| Q2 24 | -55.9% | 50.3% | ||
| Q1 24 | -22.1% | 31.4% |
| Q4 25 | 9.9% | 10.0% | ||
| Q3 25 | 3.9% | 2.1% | ||
| Q2 25 | 2.4% | 2.3% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 9.4% | 11.7% | ||
| Q3 24 | 2.2% | 3.6% | ||
| Q2 24 | 2.9% | 2.6% | ||
| Q1 24 | 4.1% | 3.5% |
| Q4 25 | — | 3.90× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 5.02× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
OFG
Segment breakdown not available.
